UK Appeal Panel Tells NICE To Revisit Scenesse Rejection

An appeals panel has upheld some of the objections to NICE’s decision not to recommend Clinuvel’s Scenesse for NHS funding in England. The HTA body’s Highly Specialized Technologies committee will now have to reconsider its guidance in light of the panel’s conclusions. 

Think again!
NICE is to reconsider its recommendation on Clinuvel's Scenesse. • Source: Shutterstock

More from Health Technology Assessment

More from Market Access